Testino Gianni, Scafato Emanuele, Patussi Valentino
Centro Alcologico Regionale, Regione Liguria, ASL 3 Genovese, Ospedale Policlinico San Martino, Genova - World Health Organization Collaborating Centre for Research and Health Promotion on Alcohol and Alcohol-related Health Problems.
World Health Organization Collaborating Centre for Research and Health Promotion on Alcohol and Alcohol-related Health Problems - Osservatorio Nazionale Alcol, Centro Nazionale Dipendenze e Doping, Istituto Superiore di Sanità, Roma.
Recenti Prog Med. 2017 Sep;108(9):366-373. doi: 10.1701/2745.27988.
Chronic alcohol related liver disease is characterized by a cascade of events defined as follows: steatosis, steatohepatitis/steatofibrosi, cirrhosis and hepatocellular carcinoma. On one of these histologic patterns may overlap acute alcoholic hepatitis (AAE) (mild, moderate, severe). Severe AAE can cause a severe clinical picture: jaundice with a duration of less than three months, jaundice in the first decompensation event, serum bilirubin higher than 5 mg/dL, ratio AST/ALT >2:1, AST less than 500 IU/L ALT <300 IU/L, neutrophil leukocytosis and increased GGT. In addition, it is possible the presence of encephalopathy, fever, fatigue, coagulopathy. The onset can also be characterized by portal hypertension-related complications. An extremely severe clinical condition is the superposition of an acute insult to a chronic framework, not necessarily a cirrhotic one. This condition has been termed acute on chronic (acute on chronic liver failure - ACLF:), and it is possible to have a SIRS (systemic inflammation response syndrome) with a multi-organ system involvement. The diagnosis, in selected cases, can be confirmed by a transjugular biopsy that allows to reach a histologic prognostic stratification. Several indices are used for the assessment of prognosis and in particular the MDF and the MELD. In our clinical practice we use the MELD. In case of ACLF, the consortium organ failure score (CLIF-C OFS) is used. The therapy is characterized by alcohol abstention, and, in severe forms (MDF >32 and MELD >21) with absence of contraindications, it is possible to use steroids therapy. If a positive answers cannot be obtained, an early liver transplantation is proposed. This possibility, after a careful selection, now is promoted by several authors.
脂肪变性、脂肪性肝炎/脂肪纤维化、肝硬化和肝细胞癌。这些组织学模式之一可能与急性酒精性肝炎(AAE)(轻度、中度、重度)重叠。重度AAE可导致严重的临床表现:黄疸持续时间少于三个月、首次失代偿事件时出现黄疸、血清胆红素高于5mg/dL、AST/ALT比值>2:1、AST低于500IU/L、ALT低于300IU/L、中性粒细胞增多和GGT升高。此外,还可能出现肝性脑病、发热、乏力、凝血功能障碍。发病也可能以门静脉高压相关并发症为特征。一种极其严重的临床情况是急性损伤叠加在慢性病变基础上,不一定是肝硬化。这种情况被称为慢加急性(慢加急性肝衰竭 - ACLF),可能会出现伴有多器官系统受累的全身炎症反应综合征(SIRS)。在某些病例中,经颈静脉活检可确诊,该活检有助于进行组织学预后分层。有几种指标用于评估预后,特别是MDF和MELD。在我们的临床实践中,我们使用MELD。对于ACLF病例,使用联合器官衰竭评分(CLIF-C OFS)。治疗的特点是戒酒,对于严重形式(MDF>32且MELD>21)且无禁忌证的患者,可使用类固醇治疗。如果无法得到肯定的答案,则建议早期肝移植。经过仔细筛选后,现在有几位作者提倡这种可能性。